iBET hosts kick-off meeting for a new malaria vaccine candidate
On July 1st, iBET hosted the kick-off meeting of the Global Health Innovative Technology (GHIT) Funded project aiming the development of an innovative malaria vaccine.
The Consortium between iBET, the Ehime University and the European Vaccine Initiative (EVI) met for the first time in Oeiras to start activities and to align expectations and responsibilities. The project team also visited iBET Laboratories including the recently rebuild Late Stage R&D and Bioproduction unit where the vaccine’s antigen will be produced.
The antigen to be incorporated in the vaccine was discovered by the Ehime University in collaboration with Sumitomo Dainippon Pharma Co., Ltd., Japan, and will now be produced at iBET before testing in animal models.
António Roldão, Senior Scientist and Group Leader of the Cell Based Vaccine Development Group said: “We are very pleased to be part of this consortium. The excitement of developing a new bioprocess for a novel vaccine is enhanced by the therapeutic potential of this second generation vaccine and the impact it can have in global health.”
More information:
GHIT press release
iBET NEWS
